A Phase 1/2, Multicenter, Dose-Escalation Study to Determine the Safety, Efficacy and Pharmacokinetics of TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

NCT00742963 Phase 1/Phase 2 COMPLETED Results posted

The purpose of this study is to determine whether TH-302 in combination with Doxorubicin is safe and effective in the treatment of Advanced Soft Tissue Sarcoma.

Details

Lead sponsor	ImmunoGenesis
Phase	Phase 1/Phase 2
Status	COMPLETED
Enrolment	107
Start date	2008-08
Completion	2013-10

Conditions

• Soft Tissue Sarcoma

Interventions

• TH-302

Primary outcomes

• Maximum Tolerated Dose (MTD) Measured of TH-302 When Used in Combination With Doxorubicin and Prophylactic Growth Factor Support in Subjects With Advanced Soft Tissue Sarcoma — Two years

Countries

United States